Work

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.179

Authors: Stephen J. Freedland, Ugo De Giorgi, Ronald F. Tutrone, Lawrence Ivan Karsh, Miguel Ramirez-Backhaus, Edward M. Uchio, Yiyun Tang, Ruslan Croitoru, Matt Rosales, Matko Kalac, Fong Wang, Neal D. Shore

Institutions: Cedars-Sinai Medical Center, Durham VA Medical Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, AdventHealth, Fundación Instituto Valenciano de Oncología, University of California, Irvine Medical Center, Pfizer (United States), Astellas Pharma (United States), Carolina Urologic Research Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4407700922

Cites:

Cited by: 1

Related to: 10